Mnemo Therapeutics, a France-based cellular therapeutics developer advancing research from Institut Curie and Memorial Sloan Kettering Cancer Center, closed a €75m ($91m) series A round on Wednesday led by Casdin Capital.
Alexandria Venture Investments, a vehicle for life sciences real estate investment trust Alexandria Real Estate Equities, backed the round, as did Redmile, Emerson Collective and Sofinnova Partners, the last of which had taken part in a seed round of undisclosed size in 2019.
Mnemo is developing CAR T cell therapies to treat cancer. Its EnfiniT drug discovery platform uses epigenetics tools to engineer T cells in order to enhance memory, persistence, sensitivity and activity, while discovering antigens with greater tumour specificity.
Alain Maiore, chief executive of Mnemo, said: “Based on the support from our premier investors and our team’s deep experience, we have completed a record-breaking series A financing in France to develop powerful cell therapies that will achieve unprecedented breakthroughs for patients with solid and blood-based cancers.”
– A version of this article first appeared on our sister site, Global Corporate Venturing.

France-based cellular therapeutics developer Mnemo Therapeutics closed a €75m ($91m) series A round on Wednesday featuring Alexandria Venture Investments, a vehicle for life sciences real estate investment trust Alexandria Real Estate Equities.

Investment firm Casdin Capital led the round, which included Redmile, Emerson Collective and Sofinnova Partners, the last of which had taken part in a seed round of undisclosed size for the company in 2019.

Mnemo is developing CAR T cell therapies to treat cancer, based on research at Institut Curie and Memorial Sloan Kettering Cancer Center.

The startup’s EnfiniT drug discovery platform uses epigenetics tools to engineer T cells in order to enhance memory, persistence, sensitivity and activity, while discovering antigens with greater tumour specificity.

Alain Maiore, Mnemo’s CEO, said: “Based on the support from our premier investors and our team’s deep experience, we have completed a record-breaking series A financing in France to develop powerful cell therapies that will achieve unprecedented breakthroughs for patients with solid and blood-based cancers.”